Histopathological Diagnosis of Nasopharyngeal Carcinoma, Patients with Nasopharyngeal Carcinoma Without Distant Metastases After AJCC/UACC 8th Edition
Conditions
Keywords
nasopharyngeal carcinoma, Peripheral blood circulating lymphocytes before treatment, CD4/CD8 ratio, Prognostic value
Brief summary
In our previous retrospective study, we identified circulating immune cell counts and the CD4/CD8 ratio as significant prognostic markers in nasopharyngeal carcinoma. Building on these findings, this study aims to conduct a multi-center prospective observational study to evaluate the prognostic value of the circulating lymphocyte CD4/CD8 ratio in nasopharyngeal carcinoma patients prior to treatment.
Interventions
None listed
Sponsors
Jiangxi Provincial Cancer Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* 1.Histopathological diagnosis of nasopharyngeal carcinoma;2.Patients with nasopharyngeal carcinoma without distant metastases after AJCC/UACC 8th edition;3.The radiation therapy technique is IMRT;4.Age 18-70 years;5.Has good organ function;6.Patients who are willing and able to comply with visit schedules, treatment plans, laboratory tests, and other study procedures; 7.Willing to comply with the arrangement during the study period and can no longer participate in any other clinical studies related to drugs and medical devices;8.Patients sign a formal informed consent form to indicate that they understand that this study is in accordance with the hospital's policies.
Exclusion criteria
* 1.Concomitant with other tumors;2.Those with a history of severe immediate allergies to any of the drugs used in this study;3.Lack of or limited capacity for civil conduct;4.Addiction to drugs or alcohol, with a physical or psychiatric disorder;5.Previous diagnosis of immunodeficiency or known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related disease;6.Pregnant or lactating female patients, male or female patients of childbearing potential who are unwilling or unable to use contraception throughout the study period and for at least 1 year after the end of the treatment regimen.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | 3 Years | The time from the first diagnosis of nasopharyngeal carcinoma to the first observation of disease progression or death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | 3 Years | The time from the first diagnosis of nasopharyngeal carcinoma to the occurrence of death from any cause |
| Distant Metastasis-free Survival | 3 years | Distant metastasis-free survival (DMFS) was defined as the time from diagnosis to the occurrence of distant metastasis or the date of censoring, whichever came first. |
| Locoregional Recurrenc-free Survival | 3 Years | Locoregional recurrence-free survival (LRRFS) was defined as the time from diagnosis to the occurrence of locoregional recurrence or the date of censoring, whichever came first. |
Countries
China
Outcome results
None listed